NCT03308448View on ClinicalTrials.gov

Traumatic Optic Neuropathy Treatment Trial 2

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 6, 2018

Primary Completion Date

August 6, 2022

Study Completion Date

March 2, 2023

Conditions
Traumatic Optic Neuropathy
Interventions
DRUG

Recombinant human erythropoietin

Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group

Trial Locations (3)

Unknown

Iran University of Medical Sciences, Tehrān

Mashhad University of Medical Sciences, Mashhad

Tehran University of Medical Sciences, Tehran

All Listed Sponsors
collaborator

Mashhad University of Medical Sciences

OTHER

collaborator

Tehran University of Medical Sciences

OTHER

lead

Iran University of Medical Sciences

OTHER

NCT03308448 - Traumatic Optic Neuropathy Treatment Trial 2 | Biotech Hunter | Biotech Hunter